265 related articles for article (PubMed ID: 9165692)
1. Current status of acid pump antagonists (reversible PPIs).
Wurst W; Hartmann M
Yale J Biol Med; 1996; 69(3):233-43. PubMed ID: 9165692
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
Huang JQ; Hunt RH
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
[TBL] [Abstract][Full Text] [Related]
3. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
4. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
5. Biological basis of omeprazole therapy.
Sachs G; Wallmark B
J Gastroenterol Hepatol; 1989; 4 Suppl 2():7-18. PubMed ID: 2562365
[TBL] [Abstract][Full Text] [Related]
6. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.
Shin JM; Cho YM; Sachs G
J Am Chem Soc; 2004 Jun; 126(25):7800-11. PubMed ID: 15212527
[TBL] [Abstract][Full Text] [Related]
7. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
[TBL] [Abstract][Full Text] [Related]
8. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors.
Lazzaroni M; Bianchi Porro G
Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S73-8. PubMed ID: 10379473
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological regulation of gastric acid secretion in the apical membrane of parietal cells; a new target for antisecretory drugs.
Okabe S; Shimosako K; Amagase K
J Physiol Pharmacol; 2001 Dec; 52(4 Pt 1):639-56. PubMed ID: 11787764
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
[TBL] [Abstract][Full Text] [Related]
11. pH, healing rate, and symptom relief in patients with GERD.
Huang JQ; Hunt RH
Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.
Shin JM; Homerin M; Domagala F; Ficheux H; Sachs G
Biochem Pharmacol; 2006 Mar; 71(6):837-49. PubMed ID: 16405921
[TBL] [Abstract][Full Text] [Related]
13. Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors.
Shamburek RD; Schubert ML
Gastroenterol Clin North Am; 1992 Sep; 21(3):527-50. PubMed ID: 1355465
[TBL] [Abstract][Full Text] [Related]
14. Animal pharmacology of reversible antagonism of the gastric acid pump, compared to standard antisecretory principles.
Kromer W; Postius S; Riedel R
Pharmacology; 2000 May; 60(4):179-87. PubMed ID: 10828742
[TBL] [Abstract][Full Text] [Related]
15. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.
Andersson K; Carlsson E
Pharmacol Ther; 2005 Dec; 108(3):294-307. PubMed ID: 16000224
[TBL] [Abstract][Full Text] [Related]
16. Validation of a conscious rat model for the discovery of novel agents that inhibit gastric acid secretion.
Campbell CA; Gaskin PJ; Darton J; Chiu P; Lee K; McLean PG
Eur J Pharmacol; 2008 Jul; 589(1-3):260-3. PubMed ID: 18571645
[TBL] [Abstract][Full Text] [Related]
17. Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection.
Martínek J; Blum AL; Stolte M; Hartmann M; Verdú EF; Lühmann R; Dorta G; Wiesel P
Aliment Pharmacol Ther; 1999 Jan; 13(1):27-34. PubMed ID: 9892876
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
Katashima M; Yamamoto K; Sugiura M; Sawada Y; Iga T
Drug Metab Dispos; 1995 Jul; 23(7):718-23. PubMed ID: 7587960
[TBL] [Abstract][Full Text] [Related]
19. Effect of omeprazole on gastric acid secretion and plasma gastrin.
Olbe L; Cederberg C; Lind T; Olausson M
J Gastroenterol Hepatol; 1989; 4 Suppl 2():19-25. PubMed ID: 2491358
[TBL] [Abstract][Full Text] [Related]
20. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers.
Galmiche JP; Bruley Des Varannes S; Ducrotté P; Sacher-Huvelin S; Vavasseur F; Taccoen A; Fiorentini P; Homerin M
Aliment Pharmacol Ther; 2004 Mar; 19(6):655-62. PubMed ID: 15023167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
